Autoimmune hepatitis laboratory findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (8 intermediate revisions by one other user not shown) | |||
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
Laboratory findings consistent with the diagnosis of [[autoimmune hepatitis]] include, increased serum [[aminotransferase]] levels (1.5-50 times reference values), Increased serum [[immunoglobulin]] levels, primarily immunoglobulin G (1.2 to 3.0 times normal) and seropositive for ANAs, anti-[[actin]], [[SMA|SMAs]], [[Liver kidney microsomal type 1 antibody|LKM-1]], anti-liver cytosol 1 (anti-LC1) [[antibodies]], SLA/LP [[autoantibodies]] or [[ANCA|pANCA]]. | |||
Laboratory findings consistent with the diagnosis of [ | |||
[ | |||
==Laboratory Findings== | ==Laboratory Findings== | ||
Following laboratory tests are used to diagnose autoimmune hepatitis: | Following laboratory tests are used to diagnose [[autoimmune hepatitis]]: | ||
*Liver function tests | *[[Liver function tests]] | ||
*Alkaline phosphatase | *[[Alkaline phosphatase]] | ||
*Antibody assays | *[[Antibody]] assays | ||
*Serum protein and immunoglobulins | *Serum [[protein]] and [[immunoglobulins]] | ||
*Complete blood count and differential count | *[[Complete blood count]] and differential count | ||
*Platelet count | *[[Platelet count]] | ||
*ESR | *[[ESR]] | ||
*Coombs test | *[[Coombs test]] | ||
*Peripheral blood film | *Peripheral blood film | ||
Laboratory findings consistent with the diagnosis of | Laboratory findings consistent with the diagnosis of [[autoimmune hepatitis]] include: | ||
*Increased serum aminotransferase levels (1.5-50 times reference values) | *Increased serum [[aminotransferase]] levels (1.5-50 times reference values) | ||
*Increased serum immunoglobulin levels, primarily immunoglobulin G (1.2 to 3.0 times normal) | *Increased serum [[immunoglobulin]] levels, primarily [[immunoglobulin]] G (1.2 to 3.0 times normal) | ||
*Seropositive for ANAs, anti-actin, SMAs, LKM-1, anti-liver cytosol 1 (anti-LC1) antibodies, SLA/LP autoantibodies or pANCA | *Seropositive for ANAs, anti-actin, SMAs, LKM-1, anti-liver cytosol 1 (anti-LC1) [[antibodies]], SLA/LP [[autoantibodies]] or pANCA | ||
{| class="wikitable" | {| class="wikitable" | ||
! colspan="2" |Revised Scoring System of the International Autoimmune Hepatitis Group | ! colspan="2" |Revised Scoring System of the International Autoimmune Hepatitis Group | ||
| Line 45: | Line 29: | ||
|- | |- | ||
| | | | ||
* AP:AST (or ALT) ratio | * AP:AST (or [[Alanine transaminase|ALT]]) ratio | ||
** <1.5 | ** <1.5 | ||
** 1.5-3 | ** 1.5-3 | ||
| Line 57: | Line 41: | ||
|- | |- | ||
| | | | ||
* Serum globulin or IgG level above ULN | * Serum [[globulin]] or [[IgG]] level above ULN | ||
** >2.0 | ** >2.0 | ||
** 1.5-2.0 | ** 1.5-2.0 | ||
| Line 72: | Line 56: | ||
|- | |- | ||
| | | | ||
* ANA, SMA, or anti-LKM1 | * [[Antinuclear antibodies|ANA]], [[SMA]], or anti-LKM1 | ||
** >1:80 | ** >1:80 | ||
** 1:80 | ** 1:80 | ||
| Line 91: | Line 75: | ||
|- | |- | ||
| | | | ||
* Hepatitis markers | * [[Hepatitis]] markers | ||
** Positive | ** Positive | ||
** Negative | ** Negative | ||
| Line 100: | Line 84: | ||
|- | |- | ||
| | | | ||
* Hepatotoxic drug exposure | * [[Hepatotoxic]] drug exposure | ||
** Positive | ** Positive | ||
** Negative | ** Negative | ||
| Line 108: | Line 92: | ||
|- | |- | ||
| | | | ||
* Average alcohol intake (g/day) | * Average [[alcohol]] intake (g/day) | ||
** <25 | ** <25 | ||
** >60 | ** >60 | ||
| Line 117: | Line 101: | ||
| | | | ||
* Histologic findings | * Histologic findings | ||
** Interface hepatitis | ** [[Interfaces|Interface]] hepatitis | ||
** Lymphoplasmacytic infiltrate | ** Lymphoplasmacytic infiltrate | ||
** Rosette formation | ** Rosette formation | ||
** Biliary changes | ** [[Biliary]] changes | ||
** Other atypical changes | ** Other atypical changes | ||
** None of above | ** None of above | ||
| Line 137: | Line 121: | ||
|- | |- | ||
| | | | ||
* Concurrent immune disease, including celiac disease | * Concurrent immune disease, including [[celiac disease]] | ||
|<nowiki>+2</nowiki> | |<nowiki>+2</nowiki> | ||
|- | |- | ||
| | | | ||
* Other autoantibodies | * Other [[autoantibodies]] | ||
|<nowiki>+2</nowiki> | |<nowiki>+2</nowiki> | ||
|- | |- | ||
| | | | ||
* HLA DRB1*03 or DRB1*04 | * [[HLA-DRB1|HLA DRB1*03]] or [[HLA-DRB1|DRB1*04]] | ||
|<nowiki>+1</nowiki> | |<nowiki>+1</nowiki> | ||
|- | |- | ||
| | | | ||
* Response to corticosteroids | * Response to [[Corticosteroid|corticosteroids]] | ||
** Complete | ** Complete | ||
** Relapse after drug withdrawal | ** Relapse after drug withdrawal | ||
| Line 161: | Line 145: | ||
** Probable autoimmune hepatitis -10 -15 | ** Probable autoimmune hepatitis -10 -15 | ||
* Aggregate score post-treatment | * Aggregate score post-treatment | ||
** Definite autoimmune hepatitis - >17 | ** Definite [[autoimmune hepatitis]] - >17 | ||
** Probable autoimmune hepatitis- 12-17 | ** Probable autoimmune hepatitis- 12-17 | ||
|- | |- | ||
| colspan="2" |AP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IgG, immunoglobulin G; | | colspan="2" |AP, [[alkaline phosphatase]]; AST, [[Aspartate transaminase|aspartate aminotransferase]]; ALT, [[alanine aminotransferase]]; IgG, [[immunoglobulin]] G; ULN-upper limit of the normal range; HLA, [[human leukocyte antigen]]; ANA, [[antinuclear antibodies]]; SMA, smooth muscle antibodies; anti-LKM1, [[antibodies]] to liver kidney microsome type 1; AMA, [[antimitochondrial antibodies]]. Adapted from Alvarez F, ''et al''. J Hepatol 1999;31:929–938, with permission of Elsevier BV and the European Association for the Study of the Liver.<ref name="pmid10580593">{{cite journal |vauthors=Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Zeniya M |title=International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis |journal=J. Hepatol. |volume=31 |issue=5 |pages=929–38 |year=1999 |pmid=10580593 |doi= |url=}}</ref><ref name="pmid18924244">{{cite journal |vauthors=Czaja AJ |title=Performance parameters of the diagnostic scoring systems for autoimmune hepatitis |journal=Hepatology |volume=48 |issue=5 |pages=1540–8 |year=2008 |pmid=18924244 |doi=10.1002/hep.22513 |url=}}</ref><ref name="pmid19675998">{{cite journal |vauthors=Wiegard C, Schramm C, Lohse AW |title=Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future |journal=Semin. Liver Dis. |volume=29 |issue=3 |pages=254–61 |year=2009 |pmid=19675998 |doi=10.1055/s-0029-1233532 |url=}}</ref> | ||
|} | |||
'''Diagnostic features of the overlap syndromes of autoimmune hepatitis''' :<ref name="pmid20304098">{{cite journal |vauthors=Kuiper EM, Zondervan PE, van Buuren HR |title=Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome |journal=Clin. Gastroenterol. Hepatol. |volume=8 |issue=6 |pages=530–4 |year=2010 |pmid=20304098 |doi=10.1016/j.cgh.2010.03.004 |url=}}</ref> | |||
{| class="wikitable" | |||
! colspan="3" |Diagnostic features of the overlap syndromes of autoimmune hepatitis | |||
|- | |||
| '''Type of overlap syndrome''' | |||
|'''Laboratory features''' | |||
|'''Serological features''' | |||
|- | |||
|AIH-[[Primary biliary cirrhosis|PBC]] | |||
|'' S''erum [[alkaline phosphatase]] (AP) level ≥2-fold ''upper limit of normal range'' (ULN) '' '' | |||
|[[Anti-mitochondrial antibody|AMA]] positive | |||
|- | |||
|AIH-[[PSC]] | |||
|[[AST]]/[[ALT]]>ULN | |||
γ-[[globulin]] and IgG >ULN | |||
[[AP]] or [[GGT]]>ULN | |||
|[[AMA]] negative | |||
|- | |||
|AIH-[[cholestatic]] syndrome | |||
|AST/ALT>ULN | |||
γ-[[globulin]] and [[IgG]] >ULN | |||
AP or GGT >ULN | |||
|[[AMA]] negative | |||
|} | |} | ||
Latest revision as of 17:28, 9 January 2018
|
Autoimmune hepatitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Autoimmune hepatitis laboratory findings On the Web |
|
American Roentgen Ray Society Images of Autoimmune hepatitis laboratory findings |
|
Risk calculators and risk factors for Autoimmune hepatitis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: :Manpreet Kaur, MD [2]
Overview
Laboratory findings consistent with the diagnosis of autoimmune hepatitis include, increased serum aminotransferase levels (1.5-50 times reference values), Increased serum immunoglobulin levels, primarily immunoglobulin G (1.2 to 3.0 times normal) and seropositive for ANAs, anti-actin, SMAs, LKM-1, anti-liver cytosol 1 (anti-LC1) antibodies, SLA/LP autoantibodies or pANCA.
Laboratory Findings
Following laboratory tests are used to diagnose autoimmune hepatitis:
- Liver function tests
- Alkaline phosphatase
- Antibody assays
- Serum protein and immunoglobulins
- Complete blood count and differential count
- Platelet count
- ESR
- Coombs test
- Peripheral blood film
Laboratory findings consistent with the diagnosis of autoimmune hepatitis include:
- Increased serum aminotransferase levels (1.5-50 times reference values)
- Increased serum immunoglobulin levels, primarily immunoglobulin G (1.2 to 3.0 times normal)
- Seropositive for ANAs, anti-actin, SMAs, LKM-1, anti-liver cytosol 1 (anti-LC1) antibodies, SLA/LP autoantibodies or pANCA
| Revised Scoring System of the International Autoimmune Hepatitis Group | |
|---|---|
| Laboratory Findings | Points |
|
+2 0 -2 |
|
+3 +2 +1 0 | |
|
+3 +2 +1 0 | |
|
-4 |
|
-3 +3 |
|
-4
+1 |
|
+2
-2 |
|
+3 +1 +1 -3 -3 -5 | |
|
+2 |
|
+2 |
| +1 | |
|
+2
+3 |
| |
| AP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; IgG, immunoglobulin G; ULN-upper limit of the normal range; HLA, human leukocyte antigen; ANA, antinuclear antibodies; SMA, smooth muscle antibodies; anti-LKM1, antibodies to liver kidney microsome type 1; AMA, antimitochondrial antibodies. Adapted from Alvarez F, et al. J Hepatol 1999;31:929–938, with permission of Elsevier BV and the European Association for the Study of the Liver.[1][2][3] | |
Diagnostic features of the overlap syndromes of autoimmune hepatitis :[4]
| Diagnostic features of the overlap syndromes of autoimmune hepatitis | ||
|---|---|---|
| Type of overlap syndrome | Laboratory features | Serological features |
| AIH-PBC | Serum alkaline phosphatase (AP) level ≥2-fold upper limit of normal range (ULN) | AMA positive |
| AIH-PSC | AST/ALT>ULN
γ-globulin and IgG >ULN |
AMA negative |
| AIH-cholestatic syndrome | AST/ALT>ULN
AP or GGT >ULN |
AMA negative |
References
- ↑ Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Büschenfelde KH, Zeniya M (1999). "International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis". J. Hepatol. 31 (5): 929–38. PMID 10580593.
- ↑ Czaja AJ (2008). "Performance parameters of the diagnostic scoring systems for autoimmune hepatitis". Hepatology. 48 (5): 1540–8. doi:10.1002/hep.22513. PMID 18924244.
- ↑ Wiegard C, Schramm C, Lohse AW (2009). "Scoring systems for the diagnosis of autoimmune hepatitis: past, present, and future". Semin. Liver Dis. 29 (3): 254–61. doi:10.1055/s-0029-1233532. PMID 19675998.
- ↑ Kuiper EM, Zondervan PE, van Buuren HR (2010). "Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome". Clin. Gastroenterol. Hepatol. 8 (6): 530–4. doi:10.1016/j.cgh.2010.03.004. PMID 20304098.